News & events

Latham Biopharm Group

Events

Latham BioPharm Group consultants attend events throughout the year to present on industry topics, research partnering opportunities and meet with potential clients. Join us at these upcoming events:

BARDA Industry Day 2018

The Latham BioPharm Group (LBG) will be in attendance at the annual BARDA Industry Day 2018 (BID 2018), where industry can learn about the U.S. Government medical countermeasure priorities, interact with BARDA and ASPR staff, and... Read More

2019 ASM Biothreats

The Latham BioPharm Group (LBG) will be attending the 2019 ASM Biothreats meeting. The focus of this meeting will be what’s new in high consequence pathogen... Read More

News

Image Description

Innovator Requirements for the Selection of a CAR-T CDMO

LBG consultants Lauren R. Schoukroun-Barnes, Joseph Rininger, Kristi Sarno, and Susan Dexter interviewed CAR-T Innovators and Manufacturers to better understand the difficulties surrounding manufacturing. Specifically, the Innovators were asked about the criteria they look for in a CDMO. Without exception, Innovator companies stated CDMO capacity and flexibility were top priorities. These criteria are priorities for Innovators because the drug product needs to be manufactured when the patient material is available. Ensuring Innovators can fulfill clinical... Read More

Outsourcing Biosimilar Development – Featured Report

LBG consultants Kristi Sarno and Cassidy Cantin performed market research and analyzed the results in an article “Outsourcing Biosimilar Development“, published in BioProcess International’s March 2017 Featured Report.  LBG interviewed six executives at companies that are either sponsoring biosimilar candidates or are CDMOs that manufacture biosimilars to identify some challenges and understand how CDMOs are adapting to capture this portion of the biopharmaceutical market. The full text of the article is available at BPI’s website or can be downloaded as a PDF here. Read More